Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

Published:2023-08 Issue:10402 Volume:402 Page:641-654
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Siddiqi Tanya,Maloney David G,Kenderian Saad S,Brander Danielle M,Dorritie Kathleen,Soumerai Jacob,Riedell Peter A,Shah Nirav N,Nath Rajneesh,Fakhri Bita,Stephens Deborah M,Ma Shuo,Feldman Tatyana,Solomon Scott R,Schuster Stephen J,Perna Serena K,Tuazon Sherilyn A,Ou San-San,Papp Eniko,Peiser Leanne,Chen Yizhe,Wierda William G

Funder

Bristol-Myers Squibb

Juno Therapeutics

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Chronic lymphocytic leukemia: a review of front-line treatment options, with a focus on elderly CLL patients;O'Reilly;Clin Lymphoma Myeloma Leuk,2018

2. Ibrutinib and venetoclax for first-line treatment of CLL;Jain;N Engl J Med,2019

3. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia;Seymour;N Engl J Med,2018

4. Current and future treatment strategies in chronic lymphocytic leukemia;Patel;J Hematol Oncol,2021

5. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia;Sharman;J Clin Oncol,2019

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice;British Journal of Haematology;2024-09-11

2. Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies;Expert Opinion on Pharmacotherapy;2024-09-08

3. CAR-T: from bench to bedside;Oncohematology;2024-09-03

4. Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia;Expert Review of Anticancer Therapy;2024-09-02

5. Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells;MedComm;2024-09